ArticleInternational journal of cancer2018

Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models.

Yong Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.